capecitabine has been researched along with Weight Loss in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alsina, M; Aranda, E; Cano, MT; Conde, V; Díaz-Rubio, E; Galán, M; García de Paredes, ML; López, C; Manzano, JL; Martínez Galán, J; Massutí, B; Pachón, V; Reboredo, M; Rivera, F; Salcedo, M; Sastre, J; Serrano, R; Valladares-Ayerbes, M; Yuste Izquierdo, AL | 1 |
| Ahn, SD; Choi, EK; Kim, JH; Kim, SB; Lee, SW; Lee, YS; Park, JW; Park, SI; Song, SY; Yoon, SM | 1 |
| Fujimoto-Ouchi, K; Mori, K; Onuma, E; Shirane, M; Tanaka, Y | 1 |
1 trial(s) available for capecitabine and Weight Loss
| Article | Year |
|---|---|
Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Endpoint Determination; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome; Weight Loss | 2015 |
2 other study(ies) available for capecitabine and Weight Loss
| Article | Year |
|---|---|
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Dose Fractionation, Radiation; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Preoperative Care; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Weight Loss | 2011 |
Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models.
Topics: Animals; Cachexia; Capecitabine; Cell Line; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Hypercalcemia; Interleukin-6; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Parathyroid Hormone-Related Protein; Tumor Cells, Cultured; Weight Loss | 2007 |